India, Jan. 4 -- Insilico Medicine announced that it has entered into a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. The partnership, valued at up to US$888 million, is focused on discovering and developing innovative oncology therapies by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development.
Under the terms of the agreement, Insilico will be eligible to receive up to US$32 million in upfront and near-term R&D payments. The company will leverage its proprietary AI-powered technologies to identify and advance potential drug candidates that meet predefined scientific and developm...